Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních věcí,
xxxxxx xx xxxx x doplňuje xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. s. x x. 46/2008 Sb. x. x. a xxxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 97/2012 Xx. x. x. x Mezinárodní xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že xxx 12. xxxxxxxxx 2012 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx znění Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx1).
S xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx dnem xxxxxxxxx x platnost x pro Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx X Xxxxxxxxxxx xxxxxx proti dopingu xx sportu xxxxxx xx 1. xxxxx 2012 a vyhlášené xxx č. 97/2012 Sb. m. s.
Anglické xxxxx Xxxxxxx X x její xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu přijatá xxx 19. xxxxx 2005 v Paříži xxxx xxxxxxxxx pod č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
PŘÍLOHA X
XXXXXX XXXXXXXXXX XXXXX X METOD DOPINGU XXX XXX 2013
XXXXXXX ANTIDOPINGOVÝ XXXXX
Xxxxxx od 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Specifické xxxxx" kromě látek xx skupin S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 a X3.
| &xxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXXXX
(PŘI XXXXXXX X XXXX SOUTĚŽ)
|
XXXXXXXX XXXXX
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX LÁTKY
Anabolické xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); xxxxxxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, prasteron (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx x xxxxxxx, xxx xx s xxxxxxxx pouze xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx anabolické xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx této xxxxx: * "exogenní" xx vztahuje x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x látce, xxxxxx xxxx tělo xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), darbepoetin (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) a xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci bílkovin xxxxx, xxxxx x xxxxxx, xxxxxx zásobení, xxxxxxx energie, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx vláken;
x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Všichni xxxx-2 xxxxxxxx xxxxxx xxxx xxxxxxxxxx optických xxxxxxx (xxxx. d- x x-), jsou xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) a xxxxxxxxxxx xxxxx xxxx podány x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx x xxxx v koncentraci xxxxx xxx 1000 xx/xx a přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx považována xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx pozitivní laboratorní xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že abnormální xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx uvedené maximum.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Xxxxxxxxx, xxxxxxxxx, toremifen, xxx xx x xxxxxxxx xxxxx xx ně.
3. Ostatní xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Cyklofenil, xxxxxxxxxxx, klomifen, xxx xx x xxxxxxxx xxxxx xx ně.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx proliferátory /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) agonists/ (xxxx. XX 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x součinnosti x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X OSTATNÍ MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, nitrožilní xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx zahrnují:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx xxxxx x té, která xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
M1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx nebo xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx a xxx podobných xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx x omezením pouze xx xx. Suplementace xxxxxxxx xxxxxxxx xxxx.
3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.
X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx integritu x xxxxxxxx Vzorků xxxxxxxxxx xxx Dopingové xxxxxxxx xx zakázané. Xx xxxxxxxx xxxxxx x/xxxx úpravu (např. xxxxxxxxxx) xxxx, ale xx s xxxxxxxx xxxxx xx ně.
2. Nitrožilní xxxxxx x/xxxx injekce více xxx 50 ml xx 6 xxxxx xxxx zakázány xxxxx xxxxxx xxxxxxxxx přijatých x průběhu xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX DOPING
Z xxxxxx potenciálu ke xxxxxxx xxxxxxxxxxx xxxxxx xx zakázáno xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx buněk;
|
LÁTKY X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 až X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx isomerů (xxxx. x- a x-) jsou xxxxxxxx, x výjimkou derivátů xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx použití x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, kokain, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Stimulancium, které xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, etamivan, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (např. nosní, xxxx aplikace) xxxx xxxx xxxxxx společně x lokálními xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx zakázány xxx xxxxxxxxxxx vyšší xxx 10 mikrogramů x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, pokud jeho xxxxxxxxxxx x xxxx xx xxxxx xxx 150 mikrogramů xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, oxykodon, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Přírodní (např. xxxxx, xxxxxx x xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, nitrožilní nebo xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX SPORTECH
|
X1. ALKOHOL
Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx rozborem xxxx. Xxxxxxx hodnota xxx porušeni xxxxxxxxxxx xxxxxxxx (hematologická hodnota) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x xxxxxxxxx U-rampa x "big air"
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (WDF)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, alprenolol, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, karteolol, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Sb. x. x. nabyl xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.